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890-2 Worsening Renal Function: What Is a Clinically 
Meaningful Change in Creatlnlne During Hsepltal ization 
With Hur t  Failure? 
Grace L. Smith. Viola Vaccarino, Mikhail Kosiborod, Judith H. Lichtman, Susan Chang, 
Harlan M. Krumholz, Yale University Schcol of Medicine, New Haven, Connecticut, 
Emory University School of Medicine, Atlanta, Georgia. 
Background: Worsening renal function (WRF) during hospitalization for heart failure 
(HF), defined as an elevation in creatinine (Cr) dudng admission, predicts poor out- 
comes, but the amount of Cr elevation that is clinically meaningful is unclear, as prior 
studies use varying definitions and focus mainly on extreme increases. 
Methods: We examined a spectrum of WRF definitions (Cr elevations >=0.2 to >=0.5 
(mg/dL)) and their associations with 6-month death, readmission, and functional decline 
after discharge in 412 hospitalized H F patients. 
Results: The sample was 51% male, 76% white, with mean age 72 years (SD 11). Mean 
admission Cr was 1.8 (SD 1.4). Frequency of WRF vaded by definition: 24% for the most 
restrictive WRF definition (Cr elevation >=0.5) to 58% for the most inclusive (>=0.2). 
Even small Cr elevations increased dsk of death, and dsks rose with higher elevations 
(Hazard Retio=1.24, 1.65, 2.12, 3.17 for elevations 0.2 to 0.5). Maximum sensitivity of 
any definition for predicting death was 64% (at •=0.2), maximum specificity was 79% (at 
>=0.5). Highest Cr elevations predicted readmission and functional decline. 
Conclualona: While larger Cr elevations predict highest risk of poor outcomes, physi- 
cians monitoring HF patients should be aware that even minor changes in renal function 
could be significant, since an elevation as low as 0.2 mg/dL is still associated with 
adverse outcomes. The "best' definition of WRF depends on the clinical context and 
should consider the tredeoffs among definitions. 
Table. Deflnltlona of WRF and outcomes. Adjusted models Include clinical and 
demogrophlc ovarlates. 
Crsatinine Sample Died 
change (%) (%) 
Adjusted Readmittsd Adjusted Functional Adjusted 
HR for (%) HR for declineor OR for 
death (95% readmission death (%) Functional 
CI) (95% CI) decline/ 
death 
(95%CI) 
WRF >=0.2 58 17 1.24 47 0.95 41 1.03 
noWRF <0.2 42 13 (0.72,2.14) 48 (0.72,1.27) 39 (0.67,1.60) 
WRF >=0.3 45 19 1.65 49 1.09 44 1.22 
noWRF <0.3 55 12 (0.95,2.84) 45 (0.92,1.45) 37 (0.79,1.90) 
WRF >=0.4 32 21 2.12 52 1.25 46 1.43 
noWRF <0.4 68 13 (1.19,3.78) 45 (0.93,1.69) 37 (0.90,2.28) 
WRF >=0.5 24 26 3.17 56 1.41 52 2.00 
noWRF <0.5 76 12 (1.74,5.78) 44 (1.02,1.94) 36 (1.19,3.36) 
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890-3 Examining the Concordance Between Patient and 
Physician Assessments of Health Status in Heart 
Failure Patients 
Mark W. Conard. John A. Spertus, Paul Heidenreich, Eric Peterson, WS Carlos Poston, 
William Weintraub, Mid America Heart/nstitute/UMKC, Kansas City Missouri. 
Background: To assess the health status of CHF patients the Kansas City Cardiomyopa- 
thy Questionnaire (KCCQ) was created and was shown to be a valid, reliable, and sensi- 
tive measure of health status in a single center. This analysis, from preliminary work by 
the Cardiovascular Outcomes Research Consortium (CORC) - a 13-canter network of 
cardiovascular centers, examines the relationship between patient-derived KCCQ 
Scores and physician assigned NYHA classification from a much more diverse popula- 
tion than originally tested with the KCCQ, 
Methods: CHF patients (N = 220) from across the US and Canada were given the KCCQ 
dudng a routine visit along with a physician-assigned NYHA classification. The mean 
scores of the 7 domains of the KCCQ were compared, using an ANOVA with tests for lin- 
eadty, against NYHA classes (Class 1=14 pts, 11=91,111=102, IV=13). 
Results: Highly significant and linear differences in mean scores by each of the seven 
KCCQ domains and NYHA classification were detected. For example, the mean KCCQ 
Overall Summary score for Class I = 77.2±18, for Class 11=67.4±21, for Class 111=53.5±.21 
and for Class IV=37.9~20; p<0.0001. 
Conclusions: These results demonstrate statistically significant concordance between 
patient and physician assessments of health status at multiple centers and as assessed 
by multiple physicians. They can help translate KCCQ scores into a metdc already famil- 
iar to most physicians. 
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890-4 Gender Is More Important Than Advancing Age as a 
Predictor of Preserved Systol ic Function in Older 
Persons Hospital ized With Heart Failure 
Frederick A. Masoudi, Grace L. Smith, Edward P. Havrenek, Ronald H. Fish, Pam Wolfe, 
Beth R. Stevens, Diana L. Ordin, Hadan M. Krumholz, JeAnne Foody, Denver Health 
Medical Center, Denver, Colorado, Colorado Foundation for Medical Care, Aurora, 
Colorado. 
Background: In populations of patients with heart failure (HF), advanced age is COnsid- 
ered one of the important correlates of preserved left ventdcular systolic function (LVSF). 
Gender and coexisting cardiovascular diseases-both correlated with advanced age-have 
also been associated with this condition. Our objective was to charactedze the group of 
patients with preserved LVSF in a national sample of older patients hospitalized with HF 
and to determine the relative magnitude of the independent correlations of gender and 
age with the syndrome. 
Methods: We conducted a cohort study with data obtained from medical charts for the 
CMS (formerly HCFA) National Heart Failure Project. Subjects were Medicare beneficis- 
des from a national sample hospitalized for HF between 4/98 and 3/99. Patients were eli- 
gible for the analysis if they were • 65 years old and had documentation of LVSE Logistic 
regression was used to adjust for demographic and clinical charectedstics. The depen- 
dent vadable was EF >0.50 or qualitative quivalent. 
Results: Of the 37,232 patient charts reviewed, 20,566 were eligible. Of these, 6,754 
(33%) had preserved LVSF. Patients with preserved LVSF were, when compared to 
those with impaired LVBF, older (mean age 79.6 vs. 78.2 years, p<0.0001), more likely 
female (71% vs. 49%, p<0.0001), less likely to have CAD, and more likely to have hyper- 
tension. After adjustment for age, race, and comorbidity, the relative odds for preserved 
LVSF were twice as high for women as for men (OR 2.10, 95% CI 1.96-2.25). Compare- 
tively, the relative odds for increasing age were small (compared to age 65-74: age 75-84 
OR 1.08, 95% CI 1.00-1.16; age 85+ OR 1.29, 95% CI 1.18-1.41). The Weld c2 statistic, 
which reflects the significance of the association, was more than an order of magnitude 
higher for gender (471) than for age (30). 
Conclusions: Among older patients with preserved LVSF hospitalized with HF, women 
are represented isproportionately, constituting almost three-quarters of this group. This 
gender dispadty was not substantially altered by adjustment for age and comorbidity. 
Further investigation should focus upon the mechanisms beyond aging to explain this 
female preponderance. 
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890-5 Carvedllol Initiation by Community  Physlclana in 
COHERE: Comparison With U.S, Carvedllol Trials and 
Compassionate Use Protocols 
Barrv M. Massie, Barry Greenberg, Edward M. Gilbert, Michael Fowler, William T. 
Abraham, Joseph A. Frenclosa, Mary Ann Lukas, Jeanenne J. Nelson, and the COHERE 
Participant Physicians, Mt. Sinai Medical School, New York, New York, WeN Medical 
College, Come/I University, New York, New York. 
Patients (Pts) and MDs participating in CHF trials may differ from those in the community. 
Clinical tdal subjects are highly selected, usually younger, more often men, and have 
fewer comorbities. Investigators are usually academic specialists with a special interest 
in CHF. As a result, generalizing trial results to community practice may be problematic. 
The Coreg ® Heart Failure Registry (COHERE) was designed to examine the use of 
carvedilol (CARV) by community MDs in unselscted Pts. The present analyses compare 
COHERE MDs and Pts with those in the U.S. CARV Tdals (CT) and the CARV compas- 
sionate use (CU) program, and specifically compare the duration and outcome of the 
titration phase. As shown in the table, COHERE MDs and Pts differed substantially from 
those in the CT and CU protocols. Although no or little difficulty with titration was reported 
in 83% of COHERE Pts, only 45% (vs 85% in CT and CU) were titreted to target CARV 
doses and more were discontinued. These results emphasize the need for observational 
studies to assess the use and outcomes of new treatments outside the clinical trial set- 
tin~]. 
Charactedstic COHERE Carvedilol CT Carvedilol CU 
Physicians(n) 633 78 NA 
Academic affiliation 41% 85%* NA 
Hospital based 6% 85%* NA 
Cardiologist 56% 91%* NA 
Patients(n) 4278 1094 2981 
Age (y) 66+13 58±12" 60~13* 
Women 35% 23%* 25%* 
LVEF 31 +12% 23+7%* NA 
NYHA Ill/IV (%) 38% 47%* 62%* 
% on ACEI 74% 95%* 95%* 
% on digoxin 56% 91%* 89%* 
% on diuretic 75% 95%* 89%* 
Titration period(deys) 74+44 NA 54±32* 
% titrated to 25/50mg bid 45% 85%* 93%* 
% discontinued 10% NA 7%* 
* P<0.00t vs COHERE 
NA = Not Available 
